智通财经网·2026-01-21 11:27Group 1 - Company subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd. received approval from the National Medical Products Administration for clinical trials of SHR-7787 injection and Adebeli monoclonal antibody injection [1] - SHR-7787 injection is a Class 1 therapeutic biological product that activates T cells to target and kill tumor cells, with a cumulative R&D investment of approximately 54.1 million yuan (unaudited) [1] Group 2 - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody that blocks the PD-1/PD-L1 pathway to reactivate the immune system's anti-tumor activity, approved for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [2] - The global sales of similar products Atezolizumab, Avelumab, and Durvalumab are projected to reach approximately 9.648 billion USD in 2024, with Atezolizumab and Durvalumab already approved for sale in China [2] - The cumulative R&D investment for Adebeli monoclonal antibody injection is approximately 1.101 billion yuan (unaudited) [2]